[Comparison between indirect and direct measurements of blood pressure].

R. Donde,A. Rabøl,M. Rahbek,O. Justesen

1974-06-24

Abstract:

What problem does this paper attempt to address?

Long-Term Effects of Simultaneous Subconjunctival and Subscleral Mitomycin C Application in Repeat Trabeculectomy

YA You,YS Gu,CT Fang,XQ Ma

DOI: https://doi.org/10.1097/00061198-200204000-00006

2002-01-01

Journal of Glaucoma

Abstract:Purpose: To assess the efficacy and safety of simultaneous mitomycin C application under conjunctival and scleral flaps in patients with repeat trabeculectomy.Methods: A total of 44 patients (44 eyes) with previous failed filtering surgery were randomized to one of two groups. The both-flaps group comprised 22 patients (22 eyes) with trabeculectomy and intraoperative mitomycin C application under conjunctival and scleral flaps, whereas the subconjunctival group comprised 22 patients (22 eyes) with subconjunctival application of mitomycin C. Particular attention was paid to intraocular pressure, postoperative medications, visual acuity, filtering bleb appearance, and complications. The mean follow-up time was 38.18 +/- 12.48 months.Results: The mean preoperative intraocular pressure decreased from 39.1 +/- 7.3 mm Hg to the postoperative level of 15.6 +/- 4.8 mm Hg in the both-flaps group (P = 0.014), and from 39.4 +/- 8.4 to 18.7 +/- 5.8 mm Hg in the subconjunctival group (P = 0.018). There was a statistically significant difference in intraocular pressure at all follow-up times, except at 1 week and 1 month postoperatively. Kaplan-Meier survival analysis showed there was no significant difference in total success rate (complete plus qualified success) between the two group, (P = 0.622, log-rank test). However, the two survival curves for the complete success subgroups (without additional medications) confirmed that mitomycin C applications under both flaps had a higher success rate than subconjunctival application (P = 0.043, log-rank test). No statistically significant difference in medications was present between the two groups, and no severe complications developed in either group.Conclusions: Trabeculectomy augmented with mitomycin C application at both sites could produce a greater lowering of intraocular pressure with low incidence of postoperative complications, and could provide an increased chance of long-term success. The procedure is effective and safe in patients with repeat trabeculectomy.
Safety and Efficacy of Mitomycin C: Augmented Trabeculectomy: Subtenon's Injection versus Sponge Application

Kanan Vimal Sedani,Purvi Raj Bhagat,Abhishek Suryakant Chauhan

DOI: https://doi.org/10.4103/ijabmr.ijabmr_154_24

Abstract:Objective: The objective of the study was to study the safety and efficacy of subtenon injection of mitomycin C (MMC) versus sponge application of MMC during trabeculectomy. Materials and methods: Thirty-seven patients having primary glaucoma warranting trabeculectomy were enrolled in the study and their forty eyes were alternately allocated into either of the two groups: subtenon injection (ST) of 0.1 mL of 0.01% of MMC or sponge application (SP) of 0.02% of MMC and were operated by a single surgeon and followed for 3 months. The outcome was analyzed primarily based on reduction in intraocular pressure (IOP) and bleb morphology. Results: Similar outcome in terms of complete success (ST - 90% and SP - 85%), qualified success (ST - 5% and SP - 5%), and failure rate (ST - 5% and SP - 10%) was seen at the end of 3 months. The absolute reduction in IOP from the baseline was -10.00 ± 3.67 mmHg (-41.2% ± 12.30) in ST versus -8.90 ± 5.56 mmHg (-35.9% ± 16.1) in the SP group at the end of 3 months. At the end of 3 months, blebs in the ST group had low-to-medium height and in the SP group had low height. Blebs in both the groups were diffuse with mild vascularity. Antiglaucoma medications required postoperatively were 0.20 ± 0.62 versus 0.40 ± 1.10 in the ST and SP group, respectively. The duration of surgery was 19.85 ± 0.75 min in the ST group versus 22.50 ± 0.51 min in the SP group. Conclusion: Subtenon injection of MMC is as efficacious and safe as the conventional sponge application technique.
Application of the Sodium Hyaluronate in Mitomycin C Trabeculectomy

陈伟,罗曼,徐永根,闵宗英

DOI: https://doi.org/10.3760/cma.j.issn.1006-4443.2008.12.019

2008-01-01

Abstract:Objective To study the application of sodium hyaluronate (SH)in mitomycin C (MMC) trabeculectomy.Methods 98 cases (116 eyes)were operated with MMC trabeculectomy.SH was injected into the anterior chamber and under the sutured scleral flaps in 52 cases(62 eyes) ,and the other 46 cases(54 eyes) as control group were jnjected into BSS.The postoperative visual acuity, intraocular pressure (IOP), filtration, forming of anterior chamber and the postoperative complications were compared between the two groups. Results The postoperative visual acuity, the forming of anterior chamber or the postoperative complications in the treatment group was better than that in the control group(P<0.01 or P<0.05).The postoperative IOP of the treatment group was(8.3±1.4)mmHg(second day),or(7.5±1.6)mmHg(1week later),or(13.2±2.4) mmHg(half a year later)averagely and that of the control group was(5.6±1.0)mmHg(P<0.05),or(6.8±1.2)mmHg(P>0.05), or(17.6±3.8)mmHg(P<0.05).All cases were followed up for 6 months to 3 years(18 months averagely).The rate of functional filtering bubles was 96.8% in the treatment group,and that in the control groupwas 85.2%(P<0.05).The successful rate was 95.2% and 81.5% respectively in two groups(P<0.05).Conclusins sodium hyaluronate using in MMC trabeculectomy can decrease the postoperative complications and elevate the successful rate.
Efficacy and safety of intraoperative injection of mitomycin C during trabeculectomy: a systematic review and meta-analysis

Jing Zheng,Ai Zhang

DOI: https://doi.org/10.1007/s10792-024-03291-7

2024-09-06

Abstract:Purpose: Trabeculectomy, a primary surgical treatment for glaucoma, often employs mitomycin C (MMC) to reduce scar formation and improve surgical outcomes. However, the optimal application method of MMC, whether by injection or sponge, remains a subject of debate. This meta-analysis aims to compare injectable and sponge-based MMC application in terms of efficacy and safety, focusing on various clinical outcomes in glaucoma patients. Methods: A comprehensive literature search of Scopus, MEDLINE, EMBASE, Ovid, Chinese biomedical literature database, China National Knowledge Infrastructure, and Cochrane Library was done for eligible studies that report data of glaucoma patients who were administered MMC by injection or sponge application during trabeculectomy. Outcomes of interest included intraocular pressure (IOP) reduction, bleb appearance grading (height, extent, vascularity), use of anti-glaucoma medications, and rates of complete success, qualified success, and failure. Data were reported as weighted mean differences (WMD) or odds ratios (OR) with confidence intervals (CI). The random-effects inverse-variance model with DerSimonian-Laird estimate of tau2 was employed, with continuity correction applied where necessary. Results: A total of 15 studies with 1276 participants were included. The meta-analysis revealed no significant difference in IOP reduction between patients treated by MMC injection and sponge application (WMD = - 0.434). Significant differences were observed in bleb appearance grading scores for height (WMD = - 0.170) and extent (WMD = 0.174), with substantial heterogeneity. The use of anti-glaucoma medications was significantly lower in the injection group (WMD = - 0.274). However, there were no significant differences in the rates of complete success, qualified success, and failure. The study demonstrated moderate to high heterogeneity across various outcomes. Conclusion: This meta-analysis indicated that while both injection and sponge methods of MMC application during trabeculectomy were equally effective for IOP reduction, they differ in their impact on bleb morphology and postoperative medication requirement. The findings highlight the need for individualized treatment approaches in glaucoma surgery, taking into account the specific needs and characteristics of each patient.
A Long-Term Study with Stringent Success Criteria

Philip Braun,Daniel Böhringer,Jens Jordan,Michael Reich,Philip Keye,Thomas Reinhard,Jan Lübke

DOI: https://doi.org/10.3390/jcm13061629

IF: 3.9

2024-03-13

Journal of Clinical Medicine

Abstract:Background: The aim was to evaluate the long-term outcome and efficacy of primary trabeculectomy with adjunctive mitomycin c (MMC) for treating glaucoma. Methods: We examined the medical records of 286 eyes that underwent trabeculectomy between 2008 and 2009 at the University Eye Hospital in Freiburg, Germany. Preoperative and follow-up data were collected, including intraocular pressure (IOP) measurements, surgical glaucoma interventions, and prescribed glaucoma medication. The first success criterion was defined as IOP ≤ 15 mmHg with no use of pressure-lowering medication by the patient, the second criterion was defined as the absence of surgical revision, and the third criterion as no further IOP-lowering surgery excluding early revisions following trabeculectomy. Statistical analyses comprised Cox regression and Kaplan–Meier survival estimations. Results: The mean follow-up duration was 1841 days (5 years). The mean preoperative IOP was 26.1 mmHg. Evaluating the success criteria at the time of average follow-up yielded a success rate of only 25% for the first criterion but 80% for both the second and third success criteria. Conclusions: The findings suggest that trabeculectomy with adjunctive MMC can be an effective procedure for permanently lowering IOP. However, surgical revisions and/or further glaucoma surgeries might still be needed. The long-term success rate is lower in comparison to previous research, which may be explained by the stricter success criteria in our study.

medicine, general & internal
Ex-press glaucoma shunt with adjunctive amniotic membrane and mitomycin C for post-traumatic glaucoma

Tong Nv-Xia,Yin Jin-Fu,Jin Xiu-Ming,Xie Xin

DOI: https://doi.org/10.3980/j.issn.1672-5123.2017.8.03

2017-01-01

International Eye Science

Abstract:AIM: To evaluate intraocular pressure (IOP) control and visual rehabilitation after placement of the Ex-press(R) miniature glaucoma shunt with adjunctive amniotic membrane transplantation (AMT) and mitomycin C (MMC) in patients with post-traumatic open-angle glaucoma during 2y of follow up.METHODS: This was an interventional,2-year,observational study.Eighteen eyes were prospectively observed (in 18 patients with traumatic secondary open-angle glaucoma) in which Ex-press miniature glaucoma filtration shunts were implanted with AMT and MMC.The outcome measures included intraocular pressure (IOP),best corrected visual acuity (BCVA),number of antiglaucoma medications,and complications.The progress of all patients was monitored for 24mo.RESULTS: Complete success (IOP <21 mmHg without glaucoma medications) was seen in 15 of the 17 (88.2%) eyes enrolled in the study at 24mo after the operation.IOP decreased from 36.9±4.8 mmHg preoperatively to 15.4±3.5 mmHg at 12mo and 15.5±3.5 mmHg at 24mo postoperatively.Early postoperative hypertension developed in two patients (11.1%) due to postoperative fibrosis.Most of the patients had improved postoperative BCVA values at the final follow-up visit compared to their preoperative measurements.Two patients (11.1%) developed transient hypotony.There were no complications such as hyphema,choroidal effusion,shallow anterior chamber,the device touching the iris,or extrusion of the device.CONCLUSION: The Ex-press miniature glaucoma filtration shunt with adjunctive AMT and MMC is effective and safe in cases of traumatic open-angle glaucoma.Surgical management is an appropriate surgical treatment in this series of cases.
The primary efficacy of trabeculectomy with immersion of mitomycin C and amniotic membrane implantation for refractory glaucoma

钟一声,程瑜,叶纹,王康孙

DOI: https://doi.org/10.3969/j.issn.1674-8115.2004.02.015

2004-01-01

Abstract:Objective To evaluate the short-term efficacy of trabeculectomy with immersion of mitomycin C and amniotic membrane implantation for refractory glaucoma. Methods Nine patients (10 eyes) of refractory glaucoma underwent trabeculectomy with immersion of mitomycin C and amniotic membrane implantation. Trabeculectomy was performed with a limbal-based conjunctival flap using 0. 4 mg/mL MMC for 3~5 min. A 6 mm x9 mm amniotic membrane was then placed under the scleral flap with 10-0 nylon suture. This group included 5 cases (6 eyes) of neovascular glaucoma, 2 (2 eyes) primary chronic angle-closure glaucoma, 1(1 eye) primary open-angle glaucoma and 1(1 eye) pseudophakic glaucoma. Results One month postoperatively, the intraocular pressure (IOP) was less than or equal to 21 mmHg in 8 eyes. The visual acuity of 5 eyes improved , 5 eyes not changed. After six months follow-up of the 7 eyes, IOP in 5 eyes was less than 21 mmHg,with appeared type Ⅰ bleb or type Ⅱ bleb. The visual acuity improved or not change in 5 eyes, reduced in 2 eyes because of fundus disease. The complications included transient hyphema, early shallow anterior chamber and exudative choroidal detachment. Conclusion Trabeculectomy with immersion of mitomycin C and amniotic membrane implantation is an effective method in the management of refractory glaucoma.
Long-term outcomes and prognostic factors for trabeculectomy with mitomycin C in eyes with uveitic glaucoma: a retrospective cohort study

Keiichiro Iwao,Masaru Inatani,Takahiko Seto,Yuji Takihara,Minako Ogata-Iwao,Satoshi Okinami,Hidenobu Tanihara

DOI: https://doi.org/10.1097/IJG.0b013e3182685167

Abstract:Purpose: To elucidate the long-term outcomes and prognostic factors for trabeculectomy with mitomycin C (MMC) in eyes with uveitic glaucoma (UG). Methods: A retrospective, consecutive, comparative cohort study was conducted with 204 patients who underwent trabeculectomy with MMC between 1999 and 2008 at 2 Japanese clinical centers. The study group included 101 eyes with UG and 103 eyes with primary open-angle glaucoma (POAG). Surgical failure was defined as intraocular pressure levels of ≥21 mm Hg or an additional glaucoma surgery. Kaplan-Meier survival curves for surgical failure were compared between UG and POAG eyes, and prognostic factors for surgical failure of trabeculectomy in UG eyes were analyzed by the Cox proportional hazards model. Secondary outcome measures included comparisons of the frequency of additional cataract surgery and other surgical complications after trabeculectomy between UG and POAG eyes. Results: The mean follow-up periods (±SD) were 34.7±37.9 and 37.7±34.7 months (median, 24.0 and 27.4 mo) for UG and POAG, respectively. The subtypes of uveitis were granulomatous uveitis (n=20) including sarcoidosis (n=12), Vogt-Koyanagi-Harada disease (n=5) and varicella zoster virus uveitis (n=3), Behçet disease (n=10), Posner-Schlossman syndrome (n=5), and other types of UG (n=12). Fifty-four eyes were diagnosed with idiopathic UG. The 3-year probabilities of success after trabeculectomy were 71.3% and 89.7% for UG and POAG, respectively (P=0.0171). A multivariable model showed that UG eyes with previous cataract surgery [relative risk (RR)=2.957, P=0.0344)] and granulomatous uveitis (RR=3.805, P=0.0106) were associated with surgical failure. UG eyes experienced more frequent cataract surgeries after trabeculectomy than POAG eyes: the 3-year probabilities of additional cataract surgery of 62.6% and 10.7% for UG and POAG, respectively (P<0.0001). There was no significant difference in the frequency of surgical complications such as bleb leakage, hypotensive maculopathy, severe anterior-chamber hemorrhage, and infectious endophthalmitis. Conclusions: Trabeculectomy with MMC was less effective in maintaining intraocular pressure reduction in UG eyes than in POAG eyes. The prognostic factors for surgical failure of trabeculectomy in UG eyes were previous cataract surgery and granulomatous uveitis. In addition, UG eyes after trabeculectomy more frequently required additional cataract surgery.
CSM enhances the filtration bleb survival in rabbit model of experimental glaucoma surgery.

Jian Ma,Xiaoning Li,Weizhong Zhang,Li Huang,Min Chen,Lei Xi,Zheng Zhang,Lihong Duan,Daping Quan,Jian Ge

DOI: https://doi.org/10.3109/02713683.2014.894079

2014-01-01

Current Eye Research

Abstract:Purpose: The aim of this study is to investigate whether CS-g-MMCs conjugate (CSM) could be a new agent to prevent the post-operative fibrosis in a rabbit model of experimental glaucoma filtration surgery. Materials and methods: In a randomized, controlled, masked-observer study, 40 New Zealand White rabbits underwent trabeculectomy in the right eyes and randomly received subconjunctival injection of phosphate buffered saline, chitosan (CS), CSM (100 mu g/ml), CSM (200 mu g/ml) or Mitomycin C (100 mu g/ml). Bleb characteristics and anterior chamber depth were evaluated by slit-lamp examination. The animals were killed on day 14 and 28. Histopathology and immunohistochemistry were performed to determine the amount of the scarring and fibrosis. Ocular toxicity was assessed by histopathology and electron microscope. Results: We found that the five groups were similar with respect to intraocular pressure and anterior chamber depth. The medians for survival days were: 5.5, 8, 17.5, 28 and 16 in the PBS, CS, CSM100, CSM200 and MMC groups, respectively. Both the CSM200 and the MMC group showed a significantly larger bleb area than the CSM100, CS and the PBS group. Less scarring was seen on day 14 and 28 in CSM200 and MMC group than in the PBS, CS and CSM100 group by histology and immunohistochemistry assessment. No damages were found in the rabbit eyes in each group. Conclusions: Subconjunctival injection of CSM postoperatively can improve the filtration bleb survival in the rabbit model. It can be a safe and effective antimetabolite in glaucoma surgery.
The physiopathological role of quinolinic acid in the mammalian central nervous system.

G. Lombardi,V. Carlá,F. Moroni

Abstract:
The efficacy of adjunctive mitomycin C and/or anti-VEGF agents on glaucoma tube shunt drainage device surgeries: a systematic review

Raquel Figueiredo,Joao Barbosa-Breda

DOI: https://doi.org/10.1007/s00417-024-06476-z

2024-04-24

Abstract:Abstract Purpose The effectiveness of mitomycin C (MMC) in trabeculectomy has long been established. The aim of this review is to evaluate the efficacy and safety of adjunctive agents in tube shunt drainage device surgery for glaucoma or ocular hypertension, since controversy still exists regarding their benefit. Methods We searched CENTRAL, PubMed, Embase, Web of Science, Scopus, and BASE for RCTs, which have used adjuvant antimetabolites—either MMC or 5-Fluorouracil (5-FU)—and/or anti-vascular endothelial growth factors (anti-VEGF) agents. The main outcome was IOP reduction at 12 months. Results Ten studies met our inclusion criteria. Nine used the Ahmed Glaucoma Valve (AGV) implant, while the double-plate Molteno implant was used in one study. Four studies used MMC. The remaining six studies used an anti-VEGF drug – either bevacizumab, ranibizumab or conbercept. Only one MMC-study reported a significant difference in the IOP reduction between groups at 12 months, favouring the MMC group (55% and 51%; p < 0.01). A significant difference was also reported by two out of five bevacizumab-studies, both favouring the bevacizumab group (55% and 51%, p < 0.05; 58% and 27%, p < 0.05), with the highest benefit seen in neovascular glaucoma cases, especially when panretinal photocoagulation (PRP) was also used. Neither ranibizumab nor conbercept were found to produce significant differences between groups regarding IOP reduction. Conclusion There is no high-quality evidence to support the use of MMC in tube shunt surgery. As for anti-VEGF agents, specifically bevacizumab, significant benefit seems to exist in neovascular glaucoma patients, especially if combined with PRP.

ophthalmology
Safety and Efficacy of Bleb Needling with Antimetabolite after Trabeculectomy Failure in Glaucoma Patients: A Systemic Review and Meta-Analysis

Xuhao Chen,Lingge Suo,Ying Hong,Chun Zhang

DOI: https://doi.org/10.1155/2020/4310258

2020-01-01

Journal of Ophthalmology

Abstract:Background. Bleb needling with subconjunctival injection of antimetabolites had become a widely accepted approach for trabeculectomy failure. However, IOP reduction effects, success rates, and complications occurrence for this procedure showed great inconsistency among the different studies. Methods. We conducted a literature search on PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. A random-effects model was performed on the extracted data based on the included studies. The intraocular pressure (IOP) and number of antiglaucomatous medications before and after the surgery were pooled for meta-analysis. The success and complication rates were estimated based on the results. Subgroup analysis, sensitivity analysis, and metaregression were applied to explore the origination of heterogeneity. Results. Thirty-seven studies with a total of 2182 patients were finally included in our review. For the present meta-analysis, the overall effects of bleb needling at the last visit revealed a reduction in IOP of 9.74 mmHg (95% confidence interval (CI) [8.85, 10.63]), 45.9% (95% CI [39.0%, 53.0%]) for complete success rate, and 70.4% (95% CI [63.5%, 77.0%]) for qualified success rate. Application of mitomycin C (MMC) and 5-fluorouracil (5-Fu) during the procedure were efficacious for IOP control during the follow-up. Metaregression revealed that possible origination of heterogeneity was baseline IOP before bleb needling, revealing a trend that higher baseline IOP correlated with a greater IOP reduction results p<0.001. For safety profile, conjunctival haemorrhage (5.7%, 95% CI [2.5%, 10.1%]), hyphema (5.5%, 95% CI [3.0%, 8.7%]), and bleb leakage (5.0%, 95% CI [3.2%, 7.3%]) had the highest estimate of incidence. An increasing number of needling was the main risk factor for needling failure. Conclusion. Bleb needling with antimetabolites could be considered an effective and safe procedure after trabeculectomy failure. After the process, patients will gain IOP control and reduce antiglaucomatous medications for at least six months with 5-Fu or MMC. Meanwhile, the overall estimates for complications were relatively low in the whole process.
AFRL-RY-WP-TR-2014-0144 DYNAMICS-ENABLED NANOELECTROMECHANICAL SYSTEMS ( NEMS ) OSCILLATORS

M. Roukes

Abstract:
Two-year outcomes of anterior versus posterior scleral application of mitomycin C-soaked sponge in trabeculectomy

Kun Hu,Fengbin Lin,Yunhe Song,Yingzhe Zhang,Ling Jin,Mengyin Liang,Robert N. Weinreb,Xiulan Zhang

DOI: https://doi.org/10.1007/s10384-023-01043-1

2024-02-07

Japanese Journal of Ophthalmology

Abstract:To compare the safety and efficacy of two different application methods of mitomycin C (MMC)-soaked sponge in trabeculectomy.

ophthalmology
Antifibrotic role of low-dose mitomycin-c-induced cellular senescence in trabeculectomy models

Le-Tien Lin,Jiann-Torng Chen,Da-Wen Lu,Ming-Cheng Tai,Chang-Min Liang,Ching-Long Chen,Shu-I Pao,Chih-Kang Hsu,Yi-Hao Chen

DOI: https://doi.org/10.1371/journal.pone.0234706

IF: 3.7

2020-06-23

PLoS ONE

Abstract:We assessed whether mitomycin-C (MMC) has different antifibrotic mechanisms in trabeculectomy wound healing.We identified 2 concentrations of MMC as "low-dose" by using WST-1 assay, Lactic dehydrogenase assay, and fluorescence-activated cell sorting flow cytometry. Senescence-associated β-galactosidase (SA-β-gal) and fibrotic gene expression was examined through immunocytochemistry, flow cytometry, real-time quantitative reverse transcription polymerase chain reaction, Western blotting, zymography, and modified scratch assay in vitro. In vivo, 0.1 mL of MMC or normal saline was injected to Tenon's capsule before trabeculectomy in a rabbit model. SA-β-gal expression, apoptotic cell death, and collagen deposition in sites treated and not treated with MMC were evaluated using terminal dUTP nick end labeling assay and histochemical staining. Bleb function and intraocular pressure (IOP) levels were examined 3, 7, 14, 21, 28, and 35 days after trabeculectomy.In vitro, human Tenon's fibroblast (HTF) senescence was confirmed by observing cell morphologic change, SA-β-gal accumulation, formation of senescence-associated heterochromatin, increased p16INK4a and p21CIP1/WAF1 expression, lower percentage of Ki-67-positive cells, and decreased COL1A1 release. Increased expression of α-SMA, COL1A1, and Smad2 signaling in TGF-β1-induced stress fibers were passivated in senescent HTFs. In addition, cellular migration enhanced by TGF-β1was inactivated. In vivo, histological examination indicated increased SA-β-gal accumulation, lower apoptosis ratios, and looser collagen deposition in sites treated with 0.2 μM MMC. Low-dose MMC-induced cellular senescence prolonged trabeculectomy bleb survival and reduced IOP levels in a rabbit model.Low-dose MMC-induced cellular senescence is involved in the antifibrotic mechanism of trabeculectomy wound healing.

multidisciplinary sciences
Reply to Comment on: 'Short-term outcomes of Mitomycin-C augmented phaco-trabeculectomy using subconjunctival injections versus soaked sponges: a randomized controlled trial'

Sabyasachi Chakrabarty,Mohideen Abdul Kader,Devendra Maheshwari,Madhavi Ramanatha Pillai,Shivkumar Chandrashekharan,Rengappa Ramakrishnan

DOI: https://doi.org/10.1038/s41433-024-03236-5

IF: 4.4563

2024-07-19

Eye

Abstract:We appreciate the interest of Yoshida et al. in our paper and thank them for their comments [1]. As suggested, we calculated the reduction in IOP from baseline at each visit and found that the differences between the two groups fail to disprove the null hypothesis. (Table 1) Table 1 Reduction in IOP from baseline in the two groups in different visits. Full size table None of the participants developed late-onset bleb leak (leakage beyond 3 months post-surgery) [2], blebitis, endophthalmitis, corneal epithelial toxicity or hypotony maculopathy. Participant 10 (injection group), developed a chronic hypotony (IOP < 6 mm Hg for more than 3 months) [3], from day 30 that recovered on the last post-operative visit.

ophthalmology
Effects of Glaucoma Treatment on Ocular Surface and Tear Functions: Comparison of Trabeculectomy and Antiglaucoma Drops

Abdussamet Mermer,Özer Dursun,Öznur Bucak,Hamide Sayar,Fatma Merve Bektaş,Pınar Eröz,Ayça Yılmaz

DOI: https://doi.org/10.4274/tjo.galenos.2024.39277

2024-10-25

Abstract:Objectives: To investigate tear function and ocular surface disease (OSD) findings in patients with glaucoma who received antiglaucoma medication in one eye and trabeculectomy surgery in the other eye. Materials and methods: The patient group included 38 eyes of 19 patients who had undergone trabeculectomy surgery with mitomycin C (MMC) treatment in one eye at least 6 months prior. These eyes were followed up without medication while the fellow eye continued receiving antiglaucomatous medication. The control group comprised 20 eyes of 20 healthy individuals. Demographic data, follow-up period after trabeculectomy, antiglaucoma medications, number of drops per day, and duration of medication were recorded. Tear break-up time (BUT), corneal and conjunctival fluorescein staining, Schirmer II test, and conjunctival impression cytology were performed. Results: A statistically significant difference was observed in BUT, corneal and conjunctival fluorescein staining, Schirmer II test, and Nelson staging levels in both eyes of patients with glaucoma compared to the control group (p=0.05). Although not statistically significant, BUT, Schirmer II test, punctate staining, and Nelson staging results showed improvement with increasing postoperative time. Conclusion: In our patient group, antiglaucoma medications and trabeculectomy surgery with MMC induced OSD to a similar degree. No superiority was observed between trabeculectomy with MMC and antiglaucoma drops in terms of OSD incidence.
The Effect of Mitomycin C on the Corneal Endothelium and Corneal Posterior Surface after Laser Subepithelial Keratomileusis

CHEN Xin-wei,CHEN Xin-yang,QI Xiao-yuan,ZHOU Hao,CHU Ren-yuan,ZHOU Xing-tao,DAI Jin-hui

DOI: https://doi.org/10.3760/cma.j.issn.1674-845x.2013.07.011

2013-01-01

Abstract:Objective To investigate the clinical effect of mitomycin C (MMC) on the corneal endothelium and corneal posterior surface after laser subepithelial keratomileusis (LASEK).Methods In a continuity prospective double-blind study,0.02％ MMC was used topically for 20 seconds in 33 eyes of 33 patients who had undergone LASEK after excimer laser ablation in the Fudan EENT Hospital.The other eye of these patients without MMC treatment was used as the control.Three and 6 months after surgery,the changes in the curve and elevation of the corneal posterior surface,and the density and variation coefficient of corneal endothelial cells were observed to evaluate the MMC toxicity.Data were analyzed using a paired t test.Results In the MMC-treated eyes,3 and 6 months after the operation,the average corneal endothelium cell density was 3353.3±290.3 cells/mm2 and 3407.6±298.4 cells/mm2; the variation coefficient was 13.36％±6.29％ and 13.48±4.34％.In the control eyes 3 and 6 months after the operation,the average corneal endothelium cell density was 3258.7±284.6 cells/mm2 and 3339.2±213.4 cells/mm2; the variation coefficient was 14.52％±7.85％ and 14.06％±6.50％.The changes in the elevation and curve of the corneal posterior surface in the MMC treated eyes were-0.67±2.26 μm and-0.52±2.67 μm and 0.01±0.20 D and 0.01±0.21 D,3 and 6 months after the operation.The changes in the control eyes were-0.85±2.31 μm and -0.15±3.00 μm and-0.01±0.22 D and 0.05+0.17 D at the respective time points after the operation.There were no significant differences in the above parameters either between preoperative or postoperative data or between these two groups.Conclusion The study showed that the application of 0.02％ mitomycin C in LASEK is safe.
The Effect of Intraoperative Mitomycin C on Refractive Stability after Laser-Assisted Subepithelial Keratomileusis in Treating High Myopia

L(U) Ya-ping,ZHOU Hao,CHU Ren-yuan,ZHOU Xing-tao,DAI Jin-hui,QU Xiao-mei,LIU Hong

DOI: https://doi.org/10.3760/cma.j.issn.1674-845x.2012.04.010

2012-01-01

Abstract:Objective To evaluate the effect of intraoperative mitomycin C on the stability of refraction after laser-assisted subepithelial keratomileusis (LASEK) in treating high myopia.Methods In this prospective control study,66 eyes of 33 patients were divided into two groups.One eye of each patient was treated with 0.02％ mitomycin C (MMC) during LASEK for myopia (MMC group) while the other eye was not treated (control group).Corneal refraction,intraocular pressure using noncontact tonometry and haze were measured at 3,6,9,12 and 15 weeks after LASEK,and the two groups were compared using paired t test.Results The difference in refraction between the 3rd week and the 6th week in the MMC group was statistically significant (t=2.254,2.175,P＜0.05),while the differences between the other adjacent time points were not statistically significant.Refraction in the MMC treatment group became stable at 9 weeks after surgery.In the control group,the refractive differences between the 3rd and 6th weeks and the 6th and 9th weeks were statistically significant (t=3.315,2.440,2.356,P＜0.05),while the differences between the other times were not significant.Refraction in the control group became stable 12 weeks after surgery.The average course and frequency of using 0.1％ fluorometholone eye drops after surgery in the MMC group were 9 weeks and 2.6 times per day while course and frequency were 12.9 weeks and 2.9 times per day for the control group.Conclusion Intraoperative MMC can shorten the refractive fluctuation time after LASEK for treating high myopia.The effect may reduce the frequency and dosage of corticosteroid eye drops after surgery and avoid the occurrence of steroid-induced ocular hypertension and glaucoma.
Anterior segment parameters after trabeculectomy in pseudoexfoliation glaucoma versus primary open-angle glaucoma

Muslum Toptan,Omer Faruk Yilmaz

DOI: https://doi.org/10.51329/mehdiophthal1497

2024-08-14

Abstract:Background: The effects of trabeculectomy on anterior segment parameters have been widely investigated. However, the stabilization time for various glaucoma types after trabeculectomy remains debatable. We investigated the effect of mitomycin C-augmented trabeculectomy on ocular anterior segment parameters in primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXG) during short-term follow-up using the Pentacam HR. Methods: In this retrospective observational study, consecutive patients diagnosed with medically uncontrolled POAG or PXG who underwent MMC-augmented trabeculectomy were recruited. All individuals underwent detailed ocular examinations. All trabeculectomies were performed by a single surgeon using the same technique. Anterior segment parameters, including anterior chamber depth (ACD), anterior chamber volume (ACV), anterior chamber angle (ACA), and central corneal thickness (CCT) were measured using the Pentacam HR, along with intraocular pressure (IOP) using a Goldmann applanation tonometer, pre-operatively and at 1-week, 1-month, and 3-month post-operative visits. Results: We included 80 patients with a median (range) age of 58.0 (41.0-86.0) years having a nearly similar sex ratio. The study groups were matched according to sex and age (both P > 0.05). The group-by-time interaction was significant for CCT and ACV (both P < 0.05) but not for IOP, ACD, and ACA (all P > 0.05). The mean (standard deviation [SD]) IOP, ACD, and ACA were comparable between groups (all P > 0.05) during the 3-month period; however, they changed significantly over time in both groups (all P < 0.001). The mean CCT and ACV were comparable between groups at each time point (all P > 0.05), except at the 1-month post-operative visit, at which the mean (SD) ACV was significantly lower in the PXG group (P < 0.05). We found a comparable mean (SD) CCT between paired visits in each group (all P > 0.05), except for the mean (SD) CCT at 3 months, which was significantly lower than that at the 1-month post-operative visit in the PXG group (P < 0.05). We found a comparable mean (SD) ACV between paired visits in each group (all P > 0.05); however, it was significantly lower at the 1-month post-operative versus the baseline visit in both groups and resumed a significantly higher value at the 1-month versus the 1-week visit and at the 3-month versus the 1-month visit in the PXG group (all P < 0.05). Conclusions: We observed significant changes in IOP, ACD, and ACA over 3 months after post-augmented trabeculectomy in eyes with POAG and PXG; however, the majority of anterior segment parameters were comparable between the two groups. Further large-scale studies with longer follow-up periods should be conducted to verify the post-operative fluctuations in these parameters in POAG and PXG.

[Comparison between indirect and direct measurements of blood pressure].

Long-Term Effects of Simultaneous Subconjunctival and Subscleral Mitomycin C Application in Repeat Trabeculectomy

Safety and Efficacy of Mitomycin C: Augmented Trabeculectomy: Subtenon's Injection versus Sponge Application

Application of the Sodium Hyaluronate in Mitomycin C Trabeculectomy

Efficacy and safety of intraoperative injection of mitomycin C during trabeculectomy: a systematic review and meta-analysis

A Long-Term Study with Stringent Success Criteria

Ex-press glaucoma shunt with adjunctive amniotic membrane and mitomycin C for post-traumatic glaucoma

The primary efficacy of trabeculectomy with immersion of mitomycin C and amniotic membrane implantation for refractory glaucoma

Long-term outcomes and prognostic factors for trabeculectomy with mitomycin C in eyes with uveitic glaucoma: a retrospective cohort study

CSM enhances the filtration bleb survival in rabbit model of experimental glaucoma surgery.

The physiopathological role of quinolinic acid in the mammalian central nervous system.

The efficacy of adjunctive mitomycin C and/or anti-VEGF agents on glaucoma tube shunt drainage device surgeries: a systematic review

Safety and Efficacy of Bleb Needling with Antimetabolite after Trabeculectomy Failure in Glaucoma Patients: A Systemic Review and Meta-Analysis

AFRL-RY-WP-TR-2014-0144 DYNAMICS-ENABLED NANOELECTROMECHANICAL SYSTEMS ( NEMS ) OSCILLATORS

Two-year outcomes of anterior versus posterior scleral application of mitomycin C-soaked sponge in trabeculectomy

Antifibrotic role of low-dose mitomycin-c-induced cellular senescence in trabeculectomy models

Reply to Comment on: 'Short-term outcomes of Mitomycin-C augmented phaco-trabeculectomy using subconjunctival injections versus soaked sponges: a randomized controlled trial'

Effects of Glaucoma Treatment on Ocular Surface and Tear Functions: Comparison of Trabeculectomy and Antiglaucoma Drops

The Effect of Mitomycin C on the Corneal Endothelium and Corneal Posterior Surface after Laser Subepithelial Keratomileusis

The Effect of Intraoperative Mitomycin C on Refractive Stability after Laser-Assisted Subepithelial Keratomileusis in Treating High Myopia

Anterior segment parameters after trabeculectomy in pseudoexfoliation glaucoma versus primary open-angle glaucoma